Harmony Biosciences Holdings HRMY
NASDAQ HRMY
$39.41 +0.12 (+0.31%)
As of: Sep 30, 2026 · 11:31 AM EDT

Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026)

Updated

Harmony Biosciences Holdings (HRMY) posted Research & Development of $46.6 million for Q2 2026, down 7.1% from $50.16 million a year earlier and down 32.8% from the prior quarter.

Analysis

Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Research & Development at Harmony Biosciences Holdings was $220.87 million, up 52.6% year-over-year; for FY2025, it came in at $189.59 million, up 30.0% from FY2024.

  • Annual Research & Development has increased for five consecutive years, with a five-year compound annual growth rate of 57.7% (FY2020 to FY2025).
  • In prior years, Harmony Biosciences Holdings' Research & Development was $145.83 million in FY2024 (+91.7%), $76.06 million in FY2023 (+7.3%), $70.89 million in FY2022 (+133.4%) and $30.37 million in FY2021 (+56.1%).
  • The Q2 2026 figure stands as the lowest quarterly Research & Development since Q1 2025.
  • On a year-over-year basis, Research & Development increased in six of the last eight quarters, with growth averaging 43.5%.
  • The strongest year-over-year quarter for Research & Development in the past five years was Q2 2024, with growth of 324.8%; the weakest was Q3 2023, with a decline of 56.8%.
  • According to Business Quant data, Research & Development for the three prior quarters was $69.38 million (Q1 2026), $49.93 million (Q4 2025) and $54.96 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Harmony Biosciences Holdings 2.33 Bn -431.22 Mn 198.08 Mn 46.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 46.60 Mn
Mar 31, 2026 69.38 Mn
Dec 31, 2025 49.93 Mn
Sep 30, 2025 54.96 Mn
Jun 30, 2025 50.16 Mn
Mar 31, 2025 34.54 Mn
Dec 31, 2024 34.67 Mn
Sep 30, 2024 25.39 Mn
Jun 30, 2024 63.58 Mn
Mar 31, 2024 22.19 Mn
Dec 31, 2023 30.31 Mn
Sep 30, 2023 17.50 Mn
Jun 30, 2023 14.97 Mn
Mar 31, 2023 13.29 Mn
Dec 31, 2022 10.09 Mn
Sep 30, 2022 40.55 Mn
Jun 30, 2022 12.67 Mn
Mar 31, 2022 7.58 Mn
Dec 31, 2021 7.45 Mn
Sep 30, 2021 11.74 Mn
API Access

Harmony Biosciences Holdings Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=HRMY&period=max&api_key=YOUR_API_KEY